Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · IEX Real-Time Price · USD
9.82
-0.41 (-4.01%)
At close: Apr 24, 2024, 4:00 PM
10.24
+0.42 (4.28%)
After-hours: Apr 24, 2024, 5:53 PM EDT

Precision BioSciences Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017
Cash & Equivalents
116.68189.58143.6689.8180.89103.1962.8
Short-Term Investments
11.9000000
Cash & Cash Equivalents
128.58189.58143.6689.8180.89103.1962.8
Cash Growth
-32.18%31.96%59.98%-50.36%75.29%64.31%-
Receivables
0.90.720.49100.970.520
Other Current Assets
6.888.8117.65.7711.8211.961.53
Total Current Assets
136.36199.11161.75105.56193.67115.6864.33
Property, Plant & Equipment
14.613.7829.3341.539.5721.158.14
Long-Term Investments
8.211.9813.720000
Goodwill and Intangibles
0.40.732.051.371.431.470.09
Other Long-Term Assets
0.2312.574.641.720.560.310.12
Total Long-Term Assets
23.4239.0649.7444.5941.5622.938.35
Total Assets
159.78238.17211.5150.16235.23138.672.68
Accounts Payable
25.380.651.140.792.042.221.81
Deferred Revenue
95.12139.0698.2684.1682.3891.2494.42
Current Debt
1.131.681.821.93000
Other Current Liabilities
-71.64-81.73-65.25-44.06-57.49-79.39-87.02
Total Current Liabilities
49.9959.6635.9842.8326.9314.089.2
Long-Term Debt
7.7223.287.298.59000
Other Long-Term Liabilities
83.2194.7977.0654.3269.9984.5789.85
Total Long-Term Liabilities
90.93118.0784.3562.969.9984.5789.85
Total Liabilities
140.92177.74120.33105.7396.9298.6499.05
Total Debt
8.8624.969.1110.52000
Debt Growth
-64.52%173.89%-13.37%----
Retained Earnings
-489.63-428.31-316.68-286.07-177.07-85.19-39.11
Shareholders' Equity
18.8660.4391.1744.43138.3139.96-26.37
Net Cash / Debt
119.72164.62134.5579.28180.89103.1962.8
Net Cash / Debt Growth
-27.27%22.35%69.72%-56.17%75.29%64.31%-
Net Cash Per Share
31.1756.1968.7845.71129.23196.24118.44
Working Capital
86.37139.44125.7762.74166.74101.655.13
Book Value Per Share
4.9120.6346.6025.6198.8275.99-49.73
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).